Fundz
New|Fundz now works inside Claude2 min

AI made execution free. Knowing first is the whole game now.

The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

VERAXA Biotech completes merger with Voyager Acquisition

PUBLIC · VRXASep 22, 2026about 3 hours ago

Acquiring Company

VERAXA Biotech

Acquired Company

Voyager Acquisition Corp

ZurichUnited StatesBiotechnologyHealth CareFinancial ServicesFinanceVenture Capital

Description

VERAXA Biotech has successfully completed its business combination with Voyager Acquisition Corp., allowing the company to enter the NASDAQ market. This merger enables VERAXA to access public markets for financing and to further develop its oncology pipeline. The merger was finalized in June 2026, marking a significant milestone in VERAXA's evolution as a public company.

Company Information

Company

VERAXA Biotech

Location

Zurich, Zurich, Switzerland

About

VERAXA Biotech is a Swiss biotechnology company focused on developing innovative oncology therapies. The company specializes in a proprietary BiTAC platform and is advancing various cancer treatment programs. With its recent entry into public markets, VERAXA aims to enhance its product development and market reach.

Fundz sees it the moment VERAXA Biotech makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Steffen
Senior decision-maker at this company
••••••••@••••••••

See Steffen's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for VERAXA Biotech's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Voyager Acquisition Corp?

Voyager Acquisition Corp was acquired by VERAXA Biotech, based in Zurich. The deal was reported on September 22, 2026. VERAXA Biotech is a Swiss biotechnology company focused on developing innovative oncology therapies. The company specializes in a proprietary BiTAC platform and is advancing various cancer treatment programs. VERAXA Biotech is publicly traded (VRXA) and operates in Biotechnology.

When did VERAXA Biotech acquire Voyager Acquisition Corp?

VERAXA Biotech's acquisition of Voyager Acquisition Corp was reported on September 22, 2026. VERAXA Biotech has successfully completed its business combination with Voyager Acquisition Corp., allowing the company to enter the NASDAQ market. This merger enables VERAXA to access public markets for financing and to further develop its oncology pipeline. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Voyager Acquisition Corp do?

Voyager Acquisition Corp. is a special purpose acquisition company (SPAC) focused on identifying and merging with high-growth potential businesses. It is privately held, operating in Financial Services, and is based in United States.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.